Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma
Abstract Background Cisplatin is a frontline anticancer drug routinely used as part of concurrent chemoradiation administered at 3-weekly (100 mg/m2) dose. However, its role as fractionated weekly dose has achieved favorable outcome in patients with locally advanced squamous cell carcinoma of head a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2021-07-01
|
| Series: | The Egyptian Journal of Otolaryngology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43163-021-00145-2 |
| _version_ | 1827279988313817088 |
|---|---|
| author | Adity Chakraborty Abhinandan Bhattacharjee Amlan Jyoti Nath Shibashis Deb Aakanksha Rathor |
| author_facet | Adity Chakraborty Abhinandan Bhattacharjee Amlan Jyoti Nath Shibashis Deb Aakanksha Rathor |
| author_sort | Adity Chakraborty |
| collection | DOAJ |
| description | Abstract Background Cisplatin is a frontline anticancer drug routinely used as part of concurrent chemoradiation administered at 3-weekly (100 mg/m2) dose. However, its role as fractionated weekly dose has achieved favorable outcome in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN) during induction chemotherapy (IC). We therefore sought to compare the toxicity outcomes of patients with LA-SCCHN treated with platinum-based IC at a single institution study using split-dose cisplatin chemotherapy. We compared the hematological and renal toxicity profile between the weekly cisplatin (30 mg/m2) (group A) versus 3-weekly (100 mg/m2) (group B) dosage schedule in this setting. Results The median age of the patients in groups A and B were 49.1 years and 48.27 years respectively with male:female ratio of 4:1. Most of the patients were of oropharyngeal cancers. Group A patients showed greater neutropenia (40.2%) than group B (20.6%). There was statistically significant fall in Hb% level in group A (13.9%) than in group B (11.9%). Renal profile showed greater rise in serum urea and serum creatinine (52.7%) in group B than in group A (52.29%) with statistically significant difference. Conclusions Since toxicities induced by high-dose cisplatin are irreversible and reduce quality of life in patients, the weekly regimen may be preferred owing to less renal toxicity, lesser hospitalization and more feasible in situations with high patient load and limited resources. |
| first_indexed | 2024-04-24T08:29:15Z |
| format | Article |
| id | doaj.art-938ea27fb97c440586399858843eebd6 |
| institution | Directory Open Access Journal |
| issn | 1012-5574 2090-8539 |
| language | English |
| last_indexed | 2024-04-24T08:29:15Z |
| publishDate | 2021-07-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Otolaryngology |
| spelling | doaj.art-938ea27fb97c440586399858843eebd62024-04-16T20:53:19ZengSpringerOpenThe Egyptian Journal of Otolaryngology1012-55742090-85392021-07-013711910.1186/s43163-021-00145-2Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinomaAdity Chakraborty0Abhinandan Bhattacharjee1Amlan Jyoti Nath2Shibashis Deb3Aakanksha Rathor4Department of Oncology, Gauhati Medical CollegeDepartment of Otolaryngology, Head Neck Surgery, Silchar Medical CollegeDepartment of Otolaryngology, Head Neck Surgery, Silchar Medical CollegeDepartment of Otolaryngology, Head Neck Surgery, Silchar Medical CollegeDepartment of Otolaryngology–Head and Neck Surgery, Stanford University School of MedicineAbstract Background Cisplatin is a frontline anticancer drug routinely used as part of concurrent chemoradiation administered at 3-weekly (100 mg/m2) dose. However, its role as fractionated weekly dose has achieved favorable outcome in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN) during induction chemotherapy (IC). We therefore sought to compare the toxicity outcomes of patients with LA-SCCHN treated with platinum-based IC at a single institution study using split-dose cisplatin chemotherapy. We compared the hematological and renal toxicity profile between the weekly cisplatin (30 mg/m2) (group A) versus 3-weekly (100 mg/m2) (group B) dosage schedule in this setting. Results The median age of the patients in groups A and B were 49.1 years and 48.27 years respectively with male:female ratio of 4:1. Most of the patients were of oropharyngeal cancers. Group A patients showed greater neutropenia (40.2%) than group B (20.6%). There was statistically significant fall in Hb% level in group A (13.9%) than in group B (11.9%). Renal profile showed greater rise in serum urea and serum creatinine (52.7%) in group B than in group A (52.29%) with statistically significant difference. Conclusions Since toxicities induced by high-dose cisplatin are irreversible and reduce quality of life in patients, the weekly regimen may be preferred owing to less renal toxicity, lesser hospitalization and more feasible in situations with high patient load and limited resources.https://doi.org/10.1186/s43163-021-00145-2Induction chemotherapySquamous cell carcinoma of head and neckHematotoxicitynephrotoxicity |
| spellingShingle | Adity Chakraborty Abhinandan Bhattacharjee Amlan Jyoti Nath Shibashis Deb Aakanksha Rathor Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma The Egyptian Journal of Otolaryngology Induction chemotherapy Squamous cell carcinoma of head and neck Hematotoxicity nephrotoxicity |
| title | Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma |
| title_full | Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma |
| title_fullStr | Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma |
| title_full_unstemmed | Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma |
| title_short | Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma |
| title_sort | comparative study on hemato and nephrotoxicity profile of weekly versus every 3 weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma |
| topic | Induction chemotherapy Squamous cell carcinoma of head and neck Hematotoxicity nephrotoxicity |
| url | https://doi.org/10.1186/s43163-021-00145-2 |
| work_keys_str_mv | AT aditychakraborty comparativestudyonhematoandnephrotoxicityprofileofweeklyversusevery3weeklycisplatindosageduringinductionchemotherapyinlocallyadvancedheadnecksquamouscellcarcinoma AT abhinandanbhattacharjee comparativestudyonhematoandnephrotoxicityprofileofweeklyversusevery3weeklycisplatindosageduringinductionchemotherapyinlocallyadvancedheadnecksquamouscellcarcinoma AT amlanjyotinath comparativestudyonhematoandnephrotoxicityprofileofweeklyversusevery3weeklycisplatindosageduringinductionchemotherapyinlocallyadvancedheadnecksquamouscellcarcinoma AT shibashisdeb comparativestudyonhematoandnephrotoxicityprofileofweeklyversusevery3weeklycisplatindosageduringinductionchemotherapyinlocallyadvancedheadnecksquamouscellcarcinoma AT aakanksharathor comparativestudyonhematoandnephrotoxicityprofileofweeklyversusevery3weeklycisplatindosageduringinductionchemotherapyinlocallyadvancedheadnecksquamouscellcarcinoma |